付绳明

[摘要] 目的 改良式經尿道双极等离子前列腺切除（PKRP）术联合M受体拮抗剂（托特罗定）对良性前列腺增生（BPH）患者的治疗效果及对患者性功能的影响。方法 方便选取2016年1月—2018年1月该院收治的BPH患者100例，按照完全随机法将所有患者分为PKRP术组和联合组，各50例。PKRP术组患者采用改良式PKRP术进行治疗，联合组患者采用改良式PKRP术联合M受体拮抗剂（托特罗定）进行治疗。评价患者术后尿道功能、性功能、射精功能、治疗效果及并发症发生情况。结果 联合治疗组患者术后最大尿流量、残余尿量、前列腺症状分别为（26.35±2.15）mL/s、（11.00±1.20）mL、（8.86±0.59）分均优于改良PKRP术组（19.25±1.06）mL/s、（20.32±2.57）mL、（6.23±0.23）分（t=20.940、23.230、29.370，P=0.001、0.001、0.001）。联合治疗组患者治疗有效率为96.00%（48/50）高于改良PKRP术组80.00%（40/50），并发症发生率为4.00%（2/50）低于改良PKRP术组18.00%（9/50）（χ2=6.061、5.005，P=0.014、0.025）。结论 BPH患者应用改良式PKRP术联合M受体拮抗剂治疗可改善患者尿道功能、性功能，效果显著，且并发症较少，安全性较高。

[关键词] 改良式经尿道双极等离子前列腺切除;M受体拮抗剂;托特罗定;良性前列腺增生

[中图分类号] R5          [文献标识码] A          [文章编号] 1674-0742（2020）07（a）-0032-03

[Abstract] Objective The effect of modified transurethral bipolar plasma prostatectomy （PKRP） combined with M receptor antagonist （tolterodine） on patients with benign prostatic hyperplasia （BPH） and its sexual function Methods 100 patients with BPH admitted to the hospital from January 2016 to January 2018 were convenient selected， and all patients were divided into PKRP surgery group and 50 patients in the combined group according to the completely random method. Patients in the PKRP group were treated with modified PKRP， and patients in the combined group were treated with modified PKRP combined with M receptor antagonist （tolterodine）. Evaluate the patients' postoperative urethral function， sexual function， ejaculation function， treatment effect and complications. Results The maximum postoperative urine flow， residual urine volume， and prostate symptoms of the combined treatment group were （26.35±2.15） mL/s，（11.00±1.20）mL，（8.86±0.59） points， which were better than the modified PKRP surgery group （19.25±1.06） mL/s， （20.32±2.57） mL， （6.23±0.23） points） （t=20.940， 23.230， 29.370，P=0.001，0.001，0.001）. The effective rate of patients in the combined treatment group was 96.00% （48/50） higher than that in the modified PKRP group 80.00% （40/50）， and the complication rate was 4.00% （2/50） lower than the modified PKRP group 18.00% （9/50） （χ2=6.061，5.005，P=0.014，0.025）. Conclusion The treatment of BPH patients with modified PKRP combined with M receptor antagonist can improve the urethral function and sexual function of patients with significant effects， fewer complications， and higher safety.

[Key words] Modified transurethral bipolar plasma prostatectomy; M receptor antagonist; Tolterodine; Benign prostatic hyperplasia